Rabies immune globulin - Kamada

Drug Profile

Rabies immune globulin - Kamada

Alternative Names: Anti-rabies IgG - Kamada; HRIG - Kamada; Human rabies immunoglobulin - Kamada; KamRAB; Rabies Ig - Kamada

Latest Information Update: 17 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kamada
  • Developer Kamada; Kedrion
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 10 Mar 2017 Vitel Laboratorios has been acquired by OncBioMune Pharmaceuticals
  • 07 Nov 2016 FDA assigns PDUFA action date of 29/08/2017 for rabies immune globulin for Rabies
  • 07 Nov 2016 US FDA accepts BLA for rabies immune globulin for Rabies for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top